Innovating.works Conecta tu I+D

ORTHO-ALLO-UNION: ORTHOpaedic treatment with ALLOgenic combined ATMP in long bone fracture delayed UNION and non union... ETABLISSEMENT FRANCAIS DU SANG participó en un HORIZON EUROPE: HORIZON-HLTH-2023-TOOL-05 Bone fracture with delay or failure to heal is a condition with huge health impact. Although only a small proportion of long bone fractures...
2023-11-28 - 2028-11-30 | financed

SUPPORT-E: SUPporting high quality evaluation of COVID 19 convalescent Plasma thrOughoutT Europe ETABLISSEMENT FRANCAIS DU SANG participó en un H2020: Coronavirus disease 19 (COVID-19) is provoking the greatest global health crisis of this generation. With no vaccine or specific antiviral t...
2020-09-02 - 2025-12-31 | financed

EVIDENCE: Erythrocytes properties and viability in dependence of flow and extra cellular environment ETABLISSEMENT FRANCAIS DU SANG participó en un H2020: H2020-MSCA-ITN-2019 After exiting the bone marrow, reticulocytes mature to form red blood cells (RBCs) which are highly adapted cells Red blood cells (RBCs) tra...
2019-08-19 - 2023-12-31 | financed

MEFISTO: MEFISTO Meniscal functionalised scaffold to prevent knee Osteoarthritis onset after meniscectomy ETABLISSEMENT FRANCAIS DU SANG participó en un H2020: H2020-NMBP-TR-IND-2018-2020 MEFISTO will develop two novel solutions to treat meniscus loss as a strategy for preventing the onset of an epidemic of post-meniscectomy k...
2019-03-05 - 2024-11-30 | financed

MAXIBONE: Personalised maxillofacial bone regeneration ETABLISSEMENT FRANCAIS DU SANG participó en un H2020: H2020-SC1-2016-2017 Several tens of millions of European citizens are partially edentulous and have insufficient bone for placement of dental implants. Followin...
2017-11-27 - 2022-06-30 | financed

ORTHOUNION: ORTHOpedic randomized clinical trial with expanded bone marrow MSC and bioceramics versus autograft... ETABLISSEMENT FRANCAIS DU SANG participó en un H2020: H2020-SC1-2016-2017 Current orthopaedic treatments permit spontaneous bone regeneration to unite and heal 90% bone injuries. Non-union associates pain and disab...
2016-12-12 - 2022-06-30 | financed

RESSTORE: REgenerative Stem cell therapy for STroke in Europe ETABLISSEMENT FRANCAIS DU SANG participó en un H2020: H2020-PHC-2014-2015 Stroke is the second leading cause of death in the world population. When not fatal, stroke often results in disability, due to motor and co...
2015-09-15 - 2020-08-31 | financed

BIOCAPAN: BIOactive implantable CApsule for PANcreatic islets immunosuppression free therapy ETABLISSEMENT FRANCAIS DU SANG participó en un H2020: H2020-NMP-2014-2015 The key therapeutic issue in diabetes mellitus type I and II is glycaemic control. Reductions of constant self-control, of insulin injection...
2015-05-29 - 2019-09-30 | financed

Ebola_Tx: Emergency evaluation of convalescent blood and plasma for Ebola Viral Disease EVD in affected West... ETABLISSEMENT FRANCAIS DU SANG participó en un H2020: DIGITAL-2024-CLOUD-AI-06 The objective of this proposal is to urgently determine the efficacy, safety and feasibility of convalescent whole blood (CWB) and convalesc...
2014-12-03 - 2016-10-31 | financed

ADIPOA2: Clinical trial of autologous adipose derived mesenchymal stromal cells ASC in the treatment of mil... ETABLISSEMENT FRANCAIS DU SANG participó en un H2020: H2020-PHC-2014-2015 Osteoarthritis (OA) is an incurable disease that has evaded pharmacological interference, biologic therapy or surgical intervention to preve...
2014-12-01 - 2019-12-31 | financed

CASCADE: Cultivated Adult Stem Cells as Alternative for Damaged tissue ETABLISSEMENT FRANCAIS DU SANG processed a FP7: Rapid progress in stem cell research pave the way for the development and use of new cell therapy products in regenerative medicine. The obj...
financed

ADIPOA: ADIPOSE DERIVED STROMAL CELLS FOR OSTEOARTHRITIS ETABLISSEMENT FRANCAIS DU SANG participó en un FP7: Osteoarthritis (OA) is a degenerative joint disease for which no efficient therapy is available. The ADIPOA consortium has previously shown...
financed

REBORNE: Regenerating Bone defects using New biomedical Engineering approaches ETABLISSEMENT FRANCAIS DU SANG participó en un FP7: Bone is among the most frequently transplanted tissue with about 1 million procedures annually in Europe. The worldwide market of bone repla...
financed

EFS